MSLN and neoplasm: Enriching mesothelin-expressing cells via cell sorting did not significantly change tumor cell killing in our assays, corroborating previous studies that highlight the high sensitivity of CAR-T cells compared with alternative strategies, such as antibody–drug conjugates or bi-specific and naked antibodies, which may require higher antigen levels to achieve comparable efficacy [72,73].